Aurobindo Pharma Enters US Dermatology Market With Launch Of ADQUEY Ointment For Atopic Dermatitis
Hyderabad-headquartered pharmaceutical giant Aurobindo Pharma Ltd announced that its US specialty subsidiary, Acrotech Biopharma Inc., has officially launched ADQUEY ointment across the United States. The milestone that came on Wednesday marks the Indian healthcare major’s strategic entry into the lucrative American dermatology segment. ADQUEY is a non-steroidal, topical phosphodiesterase-4…
Hyderabad-based pharmaceutical company Aurobindo Pharma Ltd has made its US dermatology market debut with the launch of ADQUEY ointment for atopic dermatitis. This marks the Indian healthcare leader's strategic move into the lucrative American dermatology segment. ADQUEY, a PDE4 inhibitor, targets mild-to-moderate atopic dermatitis in patients aged two years and above.
Developed by Otsuka Pharmaceutical and licensed to Acrotech for US exclusivity, the molecule comes at a time when the US therapeutic market for this condition is valued at around $1.3 billion. Aurobindo Pharma's entry into high-value branded specialty care reflects its broader strategy to move beyond generic drugs and APIs, and it's part of Acrotech Biopharma's role to expand its portfolio of branded specialty pharmaceuticals.
Acrotech's new dermatology business unit will focus on driving clinical awareness, improving patient access, and guiding treatment journeys, positioning itself for future specialty dermatology launches.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
